Test Story

By: NewsUSA

March 27, 2025 at 20:00 PM EDT

(NewsUSA) - For more details, including important safety information, on VenaSeal, visit: https://www.medtronic.com/breakfree.

Sources

Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S. doi: 10.1016/j.jvs.2011.01.079.

Mayo Clinic: Varicose Veinshttps://www.mayoclinic.org/diseases-conditions/varicose-veins/symptoms-causes/syc-20350643

National Heart Lung and Blood Institute: Varicose Veins https://www.nhlbi.nih.gov/health/varicose-veins

Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994. doi: 10.1016/j.jvs.2014.11.071.

Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European multicenter cohort study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334. doi: 10.1016/j.jvsv.2020.05.019.

Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666. doi: 10.1016/j.jvsv.2017.03.016.

Symbol	Price	Change (%)
AMZN	203.64	-3.32 (-1.60%)
AAPL	278.67	+4.99 (1.82%)
AMD	212.33	-1.24 (-0.58%)
BAC	54.67	-0.72 (-1.29%)
GOOG	311.25	-7.38 (-2.32%)
META	665.24	-5.48 (-0.82%)
MSFT	402.57	-10.70 (-2.59%)
NVDA	190.81	+2.28 (1.21%)
ORCL	155.62	-4.27 (-2.67%)
TSLA	425.18	-0.03 (-0.01%)

Symbol

Price

Change (%)

AMZN

203.64

-3.32 (-1.60%)

AAPL

278.67

+4.99 (1.82%)

AMD

212.33

-1.24 (-0.58%)

BAC

54.67

-0.72 (-1.29%)

GOOG

311.25

-7.38 (-2.32%)

Test Story

More News

Recent Quotes

Information